Improved Documentation May Help Distinguish Beta-Lactam Allergy vs Intolerance

This article is part of Infectious Disease Advisor‘s coverage of IDWeek 2018, taking place in San Francisco, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2018.

SAN FRANCISCO— A documented beta-lactam allergy was found in more than one-third of patients receiving broad-spectrum antibiotics, according to a study presented at the annual IDWeek conference, held October 3-7, 2018, in San Francisco, California.

Beta-lactam antibiotics are often indicated as first-line therapy for a diverse range of infections, and alternative therapies carry toxicities and increased risk for antimicrobial resistance. However, in the United States, allergy to beta-lactam antibiotics, especially penicillins, is the most commonly reported drug allergy. When tested for this allergy, however, only 10% of patients have a beta-lactam allergy. Patients with a documented, but usually unverified, history of beta-lactam allergy are often given excessively broad-spectrum antibiotics as alternative treatment. Because these antibiotics have differing adverse effects and toxicities and may contribute to antimicrobial resistance rate, inaccurate documentation of beta-lactam allergy has been demonstrated to effect health outcomes adversely.

Over a 6-month period, a retrospective chart review of meropenem, aztreonam, and linezolid — commonly identified as alternative treatments for individuals with beta-lactam allergy — was conducted at a county medical center. Allergy documentation, therapeutic indication, and appropriateness of therapy were analyzed in this study. For the purpose of this review, beta-lactams were defined as penicillins, penicillin derivatives, or cephalosporins.

Of the 296 cases reviewed, 257 were unique patients, of whom 35% had a documented beta-lactam reaction, although most reactions were not described effectively. Rash was the most common reaction (47%), followed by type I hypersensitivity (28%), unknown (12%), and intolerance (9%). Lower respiratory infection was the most common indication for therapy (24%). Reviewer assessment stated that 83 of 296 patients received one of theaforementioned antibiotics because of a history of beta-lactam reaction.

In conclusion, beta-lactam allergy was documented in more than one-third of patients receiving broad-spectrum antibiotics. “Improved documentation may help distinguish true allergies from intolerances and reduce broad-spectrum antibiotic use,” the study authors stated.

Visit Infectious Disease Advisor‘s conference section for continuous coverage live from IDWeek 2018.

Reference

LaNasa R, Narayan M, Ahiskali A, Zadroga R. Broad spectrum antibiotic use in relation to β-lactam allergies. Presented at: ID Week 2018; October 3-7, 2018; San Francisco, CA. Poster 35.